HOME >> BIOLOGY >> NEWS
Genomatix improves its coverage of Affymetrix new exon arrays

Genomatix Software GmbH announced today that it will extend the leading position of its gene chip compatible products further by a new version of ChipInspector, which will be specifically geared towards analysis of the new exon arrays.

"ChipInspector already revolutionized the analysis of the conventional oligo/probe based gene chips due to the powerful annotation driven analysis optimization that precedes the statistical processing of the microarray data. This feature is based on Genomatix unique knowledge and data on promoters and transcripts, which will also empower the special version optimized for the exon arrays" says Dr. Thomas Werner, CEO & CSO of Genomatix. According to Dr. Matthias Scherf, head of Genomatix Discovery team, who oversees the ChipInspector development, the new specialized version of ChipInspector will considerably improve analysis of the exon array data including transcript separation and promoter identification of the relevant transcripts.

"We have seen excellent results on pilot data from exon arrays using ChipInspector as available today" says Dr. Martin Seifert, Vice President of Microarray Business and Collaborative Research at Genomatix.

"We have brought the first complete microarray analysis pipeline to the market, that starts at the raw data and delivers the underlying biology including analysis of relevant regulatory mechanisms" explains Klaus May, Director of Sales and Marketing at Genomatix. "ChipInspector ExonArray will be a fully integrated part of this pipeline the same way as the current ChipInspector is, guaranteeing our customers superior results from raw data all the way into biology. Our pipeline delivers complete results within hours, and such speed is a great value in its own right," Klaus May continues.

ChipInspector ExonArray is expected to be released beginning of Q2 2006 and can be preordered effective immediately from Genomatix as an upgrade to ChipInspector.


'"/>

Contact: Klaus May
may@genomatix.de
49-89-599-7660
Genomatix Software GmbH
26-Jan-2006


Page: 1

Related biology news :

1. Genomatix expands operations in North America
2. Application of Genomatix in silico methods reveals novel cancer associated genes
3. Genomatix and Molecular Connections form strategic partnership
4. Genomatix wins BioChance grant worth $1.6 million
5. Genomatix appoints distributor for the growing Chinese market
6. MatBase -- A new transcription factor knowledge base released by Genomatix
7. The Center of Nutrigenomics of the TU Munich licences Genomatix Microarray Analysis Pipeline
8. Bayer HealthCare licenses Genomatix for microarray analysis
9. Genomatix technology facilitates de novo identification of new renal disease associated genes
10. Genomatix partners with Research Instruments Pte Ltd for Singapore, Malaysia and Thailand markets
11. German Microarray Excellence Center integrates Genomatix Chip Analysis Pipeline

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genomatix improves its coverage Affymetrix new exon arrays

(Date:5/21/2013)... types become most deadly when they metastasize and spread ... stage, it becomes very difficult for doctors to locate ... researchers at the University of Missouri have found a ... cells wherever they may be in the body. Michael ... College of Veterinary Medicine, says being able to target ...
(Date:5/21/2013)... available in pharmacies and health stores, phosphatidylserine is ... and soy. Proven to improve cognition and slow ... people experiencing memory impairment. Now a team headed ... of Tel Aviv University,s Department of Human ... supplement improves the functioning of genes involved in ...
(Date:5/21/2013)... Try staying fit in space, where living quarters are ... That,s the challenge a group of Michigan State University ... grant from NASA. Their goal is to keep astronauts ... could give astronauts the best exercise regimen there is, ... it, it isn,t going to help," said project leader ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... Miami, FL (PRWEB) May 21, 2013 ... and breakouts as contributor to acne. Recently physicians from ... effects of mental stress on the skin, and suggested ... to help reduce the chemicals produced from stress that ... aside from the negative feelings acne brings about, stress ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome ... use its proprietary methodologies and expertise in genomic ... kinase targets in collaboration with Blueprint Medicines.  PGDx ... at identifying genomic alterations in tumors, and Blueprint ... kinase inhibitors for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
Cached News: